0001387131-20-005353.txt : 20200601 0001387131-20-005353.hdr.sgml : 20200601 20200601065215 ACCESSION NUMBER: 0001387131-20-005353 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200601 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 20930872 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 8-K 1 txmd-8k_060120.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 1, 2020

TherapeuticsMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

001-00100

87-0233535

(State or Other Jurisdiction of

Incorporation)

(Commission File

Number)

(IRS Employer Identification No.)

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code: (561) 961-1900

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TXMD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective June 1, 2020 (the “Effective Date”), TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into an Employment Agreement with Mr. James C. D’Arecca (the “Employment Agreement”), who became Chief Financial Officer of the Company on the Effective Date. Mr. D’Arecca succeeds Mr. Daniel A. Cartwright who has retired from the Company effective on the Effective Date and will remain with the Company for a transitional period.

Prior to joining the Company, Mr. D’Arecca, age 49, served as Senior Vice President and Chief Accounting Officer of Allergan plc (formerly known as Actavis plc) from August 2013 until its merger with AbbVie Inc. in May 2020. Mr. D’Arecca was a key member of the finance team through Allergan’s journey from a generics manufacturer (Watson/Actavis) to a leading global pharmaceutical company. Mr. D’Arecca joined Actavis from Bausch & Lomb, where he served as its Chief Accounting Officer. Prior to Bausch & Lomb, Mr. D’Arecca served in various roles of increasing responsibility at Merck & Co. Inc. and Schering-Plough in finance and business development. He also spent 13 years with PricewaterhouseCoopers, with an industry focus on pharmaceuticals, medical devices, and consumer products. Mr. D’Arecca holds an M.B.A. from Columbia University and a B.S. in accounting from Rutgers University. He is a Certified Public Accountant.

Pursuant to the Employment Agreement, Mr. D’Arecca will receive an annual base salary of $420,000, subject to annual review by the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”). In addition, Mr. D’Arecca will be eligible to receive an annual performance bonus in accordance with the Company’s annual short-term incentive compensation program, with a target bonus payment equal to 75% of his base salary; any 2020 bonus paid to Mr. D’Arecca will not be prorated due to his start date with the Company. The Employment Agreement also provides for Mr. D’Arecca’s participation in customary Company benefit plans and incentive compensation plans and for Mr. D’Arecca’s entitlement to certain perquisites, benefits, and other compensation currently provided to other Company executives.

In connection with his appointment, Mr. D’Arecca will be granted pursuant to the Company’s 2019 Stock Incentive Plan (the “Plan”): (i) 651,500 restricted stock units (“RSUs”), which RSUs will vest in equal annual installments on each of June 1, 2021, 2022, and 2023, and (ii) 151,500 performance share units (“PSUs”), which PSUs will vest if the Company achieves quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) breakeven for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited, in each case subject to Mr. D’Arecca’s continued employment with the Company and the terms and conditions in the Plan and award agreements to be entered into between the Company and Mr. D’Arecca.

Upon the termination of Mr. D’Arecca’s employment for certain specified reasons, the Employment Agreement provides for severance payments of up to 12 to 18 months of Mr. D’Arecca’s base salary, a bonus for the year in which his employment terminates in an amount ranging from a pro rata portion of his bonus up to one and one-half times his bonus, depending on the basis and timing of his termination, and the continuation of certain fringe benefits for specified periods. In addition, depending on the basis for Mr. D’Arecca’s termination, all equity awards granted to Mr. D’Arecca by the Company prior to such termination will become fully vested and, if applicable, exercisable, as of the effective date of such termination. Notwithstanding the foregoing, as condition precedent to receiving any such post-termination payments or benefits, Mr. D’Arecca must execute, and not revoke, a full and complete release of all claims against the Company and its affiliates in the form attached to the Employment Agreement.

The Employment Agreement provides for customary protections of the Company’s confidential information and intellectual property and that Mr. D’Arecca will not, during the term of his employment and for a period of 18 months thereafter (subject to a 12-month extension under certain limited circumstances), compete with the Company and, for a period of 24 months thereafter, hire away from or solicit to leave the Company its employees and independent contractors, or solicit actual or targeted prospective customers or clients of the Company. The Employment Agreement has a three-year term and is subject to automatic renewals for successive one-year terms.

The foregoing description of the Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Employment Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2020.

There are no arrangements or understandings between Mr. D’Arecca and any other person pursuant to which he was appointed as an officer of the Company and no family relationship between Mr. D’Arecca and any director or executive officer of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the Company’s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which Mr. D’Arecca had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.

Mr. Cartwright’s retirement from the Company is a termination without “Cause,” as defined in that certain employment agreement, dated November 8, 2012, by and between Mr. Cartwright and the Company, and Mr. Cartwright will receive the separation benefits provided therein. Mr. Cartwright and the Company will also enter into a consulting agreement with a term of not less than three years pursuant to which Mr. Cartwright will provide financial consulting services for the Company. Under the terms of the consulting agreement, Mr. Cartwright will receive aggregate payments of $200,000 and will vest into Performance Stock Units previously issued to Mr. Cartwright.

Item 7.01

Regulation FD Disclosure.

On June 1, 2020, the Company issued a press release announcing the appointment of Mr. D’Arecca as Chief Financial Officer and concurrent retirement of Mr. Cartwright as Chief Financial Officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit Index

Exhibit Number		Description of Exhibit

99.1		Press Release from TherapeuticsMD, Inc., dated June 1, 2020, entitled “TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer”.

104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERAPEUTICSMD, INC.

Date: June 1, 2020	By:	/s/ Robert G. Finizio
		Robert G. Finizio Chief Executive Officer

EX-99.01 2 ex99-1.htm PRESS RELEASE

TherapeuticsMD, Inc. 8-K

Exhibit 99.1

FOR IMMEDIATE RELEASE

TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer and
Retirement of Daniel A. Cartwright as Chief Financial Officer

BOCA RATON, Fla., June 1, 2020 – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020. Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective June 1, 2020. Mr. Cartwright will remain with the Company as an advisor for a transitional period. Mr. D’Arecca joins TherapeuticsMD with broad experience in corporate and operational finance, most recently as Senior Vice President and Chief Accounting Officer of Allergan plc.

“I can’t imagine a more exciting time to join TherapeuticsMD,” says Mr. D’Arecca. “Having spent time in the women’s health market while at Allergan, I believe that TherapeuticsMD is well positioned to redefine women’s healthcare with a full portfolio of new and innovative products. I look forward to working with all my new colleagues as we position the company and our portfolio for continued growth.”

“I am thrilled that James has agreed to join TherapeuticsMD,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “James is a seasoned executive with a wealth of experience supporting high-growth commercially-focused pharmaceutical businesses and has a history of providing strong financial discipline and leadership. We look forward to adding James to our executive team. I believe he will help us continue our drive to build long-term shareholder value."

“I also want to congratulate Dan on his retirement,” said Mr. Finizio. “We want to thank him for nine years of outstanding service and dedication to our Company.”

About James C. D’Arecca

Prior to joining TherapeuticsMD, Mr. D'Arecca served as the Senior Vice President and Chief Accounting Officer of Allergan plc (formerly known as Actavis plc) from August 2013 until its merger with AbbVie Inc. in May 2020. Mr. D’Arecca was a key member of the finance team through Allergan’s journey from a generics manufacturer (Watson/Actavis) to a leading global pharmaceutical company. Mr. D’Arecca joined Actavis from Bausch & Lomb, where he served as its Chief Accounting Officer. Prior to Bausch & Lomb, he served in various roles of increasing responsibility at Merck & Co. Inc. and Schering-Plough in finance and business development. He also spent 13 years with PricewaterhouseCoopers, with an industry focus on pharmaceuticals, medical devices, and consumer products. Mr. D'Arecca earned his MBA from Columbia University, his B.S. in accounting from Rutgers University, and is a Certified Public Accountant.

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the Company’s ability to protect the intellectual property related to its products; the effects of the COVID-19 pandemic; the Company’s ability to maintain or increase sales of its products; the Company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the Company will be able to comply with the covenants and conditions under its term loan facility, including the conditions to draw an additional tranche thereunder and whether the lender will make such tranche available; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the Company’s current or future approved products or preclude the approval of the Company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the Company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the Company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the Company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the Company’s licensees to commercialize and distribute the Company’s products; the ability of the Company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the Company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the Company’s common stock and the concentration of power in its stock ownership. PDF copies of the Company’s historical press releases and financial tables can be viewed and downloaded at it website: www.therapeuticsmd.com/pressreleases.aspx.

# # #

Investor Contact

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088

Nochsner@TherapeuticsMD.com

EX-101.SCH 3 txmd-20200601.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 txmd-20200601_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 5 txmd-20200601_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 ex99-1_img001.jpg GRAPHIC begin 644 ex99-1_img001.jpg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end XML 7 txmd-8k_060120_htm.xml IDEA: XBRL DOCUMENT 0000025743 2020-06-01 2020-06-01 iso4217:USD shares iso4217:USD shares 0000025743 false 8-K 2020-06-01 TherapeuticsMD, Inc. NV 001-00100 87-0233535 951 Yamato Road Suite 220 Boca Raton FL 33431 (561) 961-1900 Not Applicable false false false false Common Stock, par value $0.001 per share TXMD NASDAQ false JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "txmd-8k_060120.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "txmd-8k_060120.htm" ] }, "labelLink": { "local": [ "txmd-20200601_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "txmd-20200601_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "txmd-20200601.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TXMD", "nsuri": "http://therapeuticsmd.com/20200601", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "txmd-8k_060120.htm", "contextRef": "From2020-06-01to2020-06-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://therapeuticsmd.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "txmd-8k_060120.htm", "contextRef": "From2020-06-01to2020-06-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 01, 2020
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 01, 2020
Entity File Number	001-00100
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Entity Tax Identification Number	87-0233535
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	951 Yamato Road
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	(561)
Local Phone Number	961-1900
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TXMD
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Information, Former Legal or Registered Name	Not Applicable

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-20-005353-xbrl.zip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end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://therapeuticsmd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports txmd-8k_060120.htm ex99-1.htm txmd-20200601.xsd txmd-20200601_lab.xml txmd-20200601_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}